Ozempic-maker Novo open to upgrading US listing
Boss Mike Doustdar says he sees ‘advantages’ in giving US investors direct access to Danish group’s stock
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.ft.com — the content belongs to Financial Times.
